Martin Vollmer, Agilent Biopharma Program Manager, commented on the collaboration, saying, “The collaboration between Merck and Agilent on the integration of PAT is an important milestone. It combines expertise in analytical measurement with fully automated bioprocessing, enabling real-time release for biological products in the context of Biopharma 4.0. This initiative aims to decrease errors, speed up processes, and reduce costs in bioprocessing.”

The system, ideal for non-chromatography experts, can be integrated into batch or continuous bioprocessing. It uses online HPLC with direct sampling capabilities, with Merck’s MAST (Modular Automated Sampling Technology) Platform ensuring automatic and sterile sampling. The Online LC can also be used for downstream processing triggering continuous aggregate removal and facilitate real-time process control and sample preparation steps. 

The system has a broad range of applications, encompassing virtually any bioreaction where cells are produced. It is particularly relevant in the biopharmaceutical sector, including areas such as monoclonal antibody (mAb) production and cell therapy. It offers time and cost savings and can be used in both upstream and downstream bioprocessing applications, as demonstrated in available case studies. The collaboration brings benefits such as real-time analysis, automation, quality assurance, and optimization.